Geode Capital Management LLC Has $4.22 Million Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Geode Capital Management LLC raised its stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 10.2% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,264,166 shares of the company’s stock after purchasing an additional 117,418 shares during the quarter. Geode Capital Management LLC owned approximately 1.64% of Trevi Therapeutics worth $4,223,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in TRVI. BNP Paribas Financial Markets grew its stake in shares of Trevi Therapeutics by 130.9% in the third quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock valued at $40,000 after buying an additional 6,764 shares in the last quarter. American Century Companies Inc. grew its position in shares of Trevi Therapeutics by 17.1% in the 2nd quarter. American Century Companies Inc. now owns 54,108 shares of the company’s stock valued at $161,000 after acquiring an additional 7,902 shares during the period. MAI Capital Management increased its stake in shares of Trevi Therapeutics by 0.7% during the 3rd quarter. MAI Capital Management now owns 1,327,285 shares of the company’s stock worth $4,433,000 after purchasing an additional 8,789 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Trevi Therapeutics by 87.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company’s stock valued at $73,000 after purchasing an additional 11,450 shares during the period. Finally, Intech Investment Management LLC acquired a new stake in Trevi Therapeutics in the 3rd quarter valued at about $63,000. Institutional investors and hedge funds own 95.76% of the company’s stock.

Trevi Therapeutics Price Performance

Trevi Therapeutics stock opened at $4.59 on Monday. The firm has a market cap of $352.81 million, a PE ratio of -10.43 and a beta of 0.96. Trevi Therapeutics, Inc. has a one year low of $1.27 and a one year high of $4.68. The stock’s fifty day moving average price is $3.31 and its two-hundred day moving average price is $3.10.

Trevi Therapeutics (NASDAQ:TRVI) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). During the same quarter last year, the business earned ($0.08) earnings per share. Sell-side analysts expect that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on TRVI shares. D. Boral Capital reissued a “buy” rating and set a $21.00 price target on shares of Trevi Therapeutics in a research report on Thursday, December 12th. HC Wainwright boosted their target price on Trevi Therapeutics from $6.00 to $7.50 and gave the stock a “buy” rating in a report on Thursday, December 12th. Leerink Partners began coverage on Trevi Therapeutics in a report on Monday, September 9th. They set an “outperform” rating and a $7.00 price target for the company. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price objective on shares of Trevi Therapeutics in a report on Thursday, December 12th. Finally, Leerink Partnrs upgraded shares of Trevi Therapeutics to a “strong-buy” rating in a research note on Monday, September 9th. Eight analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Trevi Therapeutics has an average rating of “Buy” and a consensus price target of $9.31.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.